My name is Brian Longbottom, MD. I am a #T32 Research Fellow in Surgical Oncology at @UTMDAnderson and pursuing the MS in Clinical Research @McGovernMed. I will start sharing Breast & HPB Surg Onc content regularly. Please share and follow! #SurgOnc#BreastSurgery#HPBSurgery
🚨🆕🗞️ Frailty's toll after surgery isn't mainly more complications. It's failing to survive them.
1.6M NSQIP pts 65+: 70% of frailty-related excess deaths ran through failure to rescue. Most frail hit 5% post-complication mortality in 2 days vs 13.
authors.elsevier.com/c/1o7C2…
#ScienceSaturday
🧬 What if we could help the immune system’s cancer-fighting T cells regain their ability to attack tumors, even after they become exhausted?
🔬 New research published in Nature identifies a potential way to do just that. Scientists found that targeting a protein called ZMYND8 can restore signaling pathways that help CD8+ T cells maintain their cancer-killing abilities, rather than progressing toward a more dysfunctional state.
🛡️ Why does this matter? T-cell exhaustion is a major challenge in cancer #immunotherapy. When T cells are exposed to persistent signals from cancer cells, they can gradually lose their ability to mount an effective attack. Researchers found that removing ZMYND8’s inhibitory influence strengthened IL-2 signaling, which helps support T-cell activity and function.
💡 The findings are especially promising because targeting ZMYND8 enhanced antitumor activity in preclinical models, particularly when combined with IL-2 therapy or immune checkpoint blockade. The researchers also observed improvements in human T cells in laboratory studies, offering insight into the potential relevance of this approach.
🚀 Although more research is needed before this strategy can be translated into patient care, the study offers a new avenue for investigating how we might strengthen the immune system’s response to #cancer.
📖 Read the full study in Nature:
nature.com/articles/s41586-0…@hongbo_chi@StJudeResearch@StJude
🚨 Big news today!! FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma !!!🚨
fda.gov/drugs/resources-info…
Some of the best surgical education happens outside the home institution—learning donor anatomy, procurement techniques, and the responsibility that comes with honoring the gift of donation. @Sharpknife_Aziz
Honored and humbled to receive the Excellence in Clinical Coaching Award from the GME program at @uiowa . Grateful to work alongside incredible residents, fellows, mentors, and colleagues who make teaching and learning such a rewarding journey.
Hot off the press. Check out our latest publication from the UIowa Surgery Surgical Outcomes group. @Sharpknife_Aziz
Evaluating the Role of Surgical Approach in Frail Patients Undergoing ... sciencedirect.com/science/ar…
Thrilled to receive the 2026 Foundation Award from the @CentralSurg to study how age influences access to curative surgery. Grateful to my mentors and team for supporting this work. @uiowa . A Big Win for the Surgical Outcomes group at the University of Iowa.
📣 Announcement
Please join us in congratulating Dr. Hassan Aziz on his appointment as the newest Associate Editor for the Gastrointestinal Surgery (HPB) section. He also serves as our Social Media Editor, and we are excited to continue working together in this expanded role.
New publication ! @JSurgEduc@UIowa_Surgery
We surveyed residents across the U.S. to understand how they are trained, supported, and supervised when obtaining procedural consent — a key patient safety and communication responsibility.
full-text link: authors.elsevier.com/a/1m8PL…